Tetherin/BST2, a physiologically and therapeutically relevant regulator of platelet receptor signalling

Xiaojuan Zhao,1 Dominic Alibhai,2 Ting Sun,3 Jawad Khalil,1 James L. Hutchinson,1 Kaya Olzak,1 Christopher M. Williams,1 Yong Li,1 Richard Sessions,4 Stephen Cross,2 Richard Seager,1 Riyaad Aungraheeta,1 Alan Leard,2 Caroline M. McKinnon,4 David Phillips,1 Lei Zhang,9 Alastair W. Poole,1 George Banting,4 and Stuart J. Mundell1

1School of Physiology, Pharmacology, and Neuroscience, and 2Wolfson Bioimaging Facility, University of Bristol, Bristol, United Kingdom; 3State Key Laboratory of Experimental Hematology, Key Laboratory of Gene Therapy for Blood Disease, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China; and 4School of Biochemistry, University of Bristol, Bristol, United Kingdom

Introduction

Platelets are important mediators of thrombosis in both healthy and diseased vessels, which, when activated by blood vessel injury, form hemostatic thrombi. Pathological activation of platelets can induce occlusive thrombosis, resulting in ischemic events such as heart attack and stroke.1 In addition, through their intrinsic ability to store and secrete a multitude of factors, platelets are implicated in the progression of atherosclerotic plaques, which ultimately contribute to the development of coronary artery disease.2-4 Platelets are recruited to sites of injury and activated by a variety of stimuli, including collagen, thrombin, and von Willebrand factor.5-8 During activation, platelets release a multitude of prothrombotic and proinflammatory factors, including adenosine diphosphate (ADP), serotonin, and granule contents.9-11 These events contribute to the formation of hemostatic thrombi that can lead to atherothrombosis and vascular occlusion.12-14

The reactivity of platelets, which play a key role in the pathogenesis of atherothrombosis, is tightly regulated. The integral membrane protein tetherin/bone marrow stromal antigen-2 (BST-2) regulates membrane organization, altering both lipid and protein distribution within the plasma membrane. Because membrane microdomains have an established role in platelet receptor biology, we sought to characterize the physiological relevance of tetherin/BST-2 in those cells. To characterize the potential importance of tetherin/BST-2 to platelet function, we used tetherin/BST-2−/− murine platelets. In the mice, we found enhanced function and signaling downstream of a subset of membrane microdomain–expressing receptors, including the P2Y12, TP thromboxane, thrombin, and GPVI receptors. Preliminary studies in humans have revealed that treatment with interferon-α (IFN-α), which upregulates platelet tetherin/BST-2 expression, also reduces adenosine diphosphate–stimulated platelet receptor function and reactivity. A more comprehensive understanding of how tetherin/BST-2 negatively regulates receptor function was provided in cell line experiments, where we focused on the therapeutically relevant P2Y12 Receptor (P2Y12R). Tetherin/BST-2 expression reduced both P2Y12R activation and trafficking, which was accompanied by reduced receptor lateral mobility specifically within membrane microdomains. In fluorescence lifetime imaging-Förster resonance energy transfer (FLIM-FRET)–based experiments, agonist stimulation reduced basal association between P2Y12R and tetherin/BST-2. Notably, the glycosylphosphatidylinositol (GPI) anchor of tetherin/BST-2 was required for both receptor interaction and observed functional effects. In summary, we established, for the first time, a fundamental role of the ubiquitously expressed protein tetherin/BST-2 in negatively regulating membrane microdomain–expressed platelet receptor function.
of numerous diseases ranging from cancer to viral infection. Platelet activation is a tightly coordinated process involving the integrated activation of multiple cell surface–expressed receptors. As in other cells, this highly coordinated process is dependent on the localization of a specific repertoire of transducing, enzymatic, and regulatory kinases and phosphatases that shape signaling output.

Membrane microdomains (also known as lipid rafts) are small (10-200 nm), heterogeneous, highly dynamic, ordered membrane domains enriched in cholesterol, sphingolipids, and gangliosides. These lipid-enriched regions behave as signaling platforms, mediating a host of signal transduction, intracellular vesicle trafficking, cell fate specification, and disease processes. Human platelets express several surface receptors that have functions that are dependent on their expression in membrane microdomains, including the G protein–coupled thromboxane A2 (TP) and P2Y12 receptors (P2Y12Rs). Little is known about the identities of the proteins in platelets or other cells that coordinate surface receptor distribution into membrane microdomains. Furthermore, the importance of such proteins in the regulation of receptor function remains unclear.

Tetherin, also known as bone marrow stromal antigen-2 (BST-2), CD317, or HM1.24 antigen, is an integral membrane protein with a novel topology ubiquitously expressed in a variety of cells. After it was identified as a marker for bone marrow stromal cells and various tumor cells, it became clear that tetherin/BST-2 is much more widely expressed in a variety of cells, including hepatocytes, pneumocytes, activated T cells, monocytes, plasmacytoid dendritic cells, ducts of major salivary glands, pancreatic and kidney cells, and the vascular endothelium. Transcriptome analysis has shown that tetherin/BST-2 is also expressed in both human and mouse platelets. Tetherin/BST-2 is associated with a plethora of biological processes, including restriction of enveloped virus release, regulation of B-cell growth, and organization of membrane microdomains.

Tetherin/BST-2 is a type 2 single-pass transmembrane protein with unusual architecture, comprising a short cytoplasmic tail at the N terminus, followed by a transmembrane (TM) region, a coiled-coil extracellular domain (ED) containing cysteines (C53/C63/C91) that is necessary for stabilizing dimerization, and a glycosylphosphatidylinositol (GPI) anchor at the C terminus. In relation to viral release, this unique molecular structure allows it to physically tether viral membranes to the host cell membrane, thereby retaining the virus on the cell surface.

In addition to the roles of tetherin/BST-2 in antiviral immunity, we and others have established that it is an organizer of different cellular structures and organelles. Work from our laboratory was the first to establish that tetherin/BST-2 is necessary for the maintenance of the apical actin network and microvilli in polarized epithelial cells. At the cell surface, tetherin/BST-2 is proposed to decorate the perimeter of membrane microdomains serving as a picket fence linked to the underlying actin cytoskeleton to stabilize and organize these regions. The GPI anchor of tetherin localizes the protein to cholesterol-rich regions of the cell membrane, whereas the TM domain of the protein sits outside these regions. Reduced tetherin expression has been suggested to change the distribution of membrane-localized proteins and organization of lipids in the plasma membrane.

Although tetherin/BST-2 is ubiquitously expressed, the physiological significance of this protein in relation to receptor biology is unclear. We hypothesized that tetherin/BST-2 expression is essential for normal platelet receptor function and demonstrate for the first time that tetherin/BST-2 negatively regulates platelet receptor signaling.

**Methods**

**Materials**

All materials and reagents used in this study are described in the supplemental Methods.

**Animals**

Tetherin/BST-2−/− mice were a kind gift from Paul D. Bienia (The Rockefeller University, New York, NY). Tetherin/BST-2−/− mice were maintained on a mixed C57BL/6 background, and littermates were used as the control, with genotyping of tetherin/BST-2−/−, as previously described. All procedures undertaken complied with the Animals (Scientific Procedures) Act 1986 (licenses 30/2386 and 30/2908) and were approved by the University of Bristol’s local Research Ethics Committee.

**Patient-based experiments**

Patients with an essential thrombocythemia (ET) diagnosis, according to World Health Organization 2001/2008 diagnostic criteria, were enrolled in this study. Four patients had blood samples collected before initiation of interferon-α2b (IFN-α2b) therapy, another 4 were treated with pegylated IFN-α2b (40 μg every other day for 5-23 months). Appropriate informed consent was obtained from all patients before blood was collected, in accordance with the Declaration of Helsinki and under a research protocol approved by the ethics committees of the Chinese Academy of Medical Sciences and Peking Union Medical College.

**Platelet aggregation and ATP secretion**

Platelet preparation, aggregation, and adenosine triphosphate (ATP) secretion were undertaken as previously described and as detailed in the supplemental Methods.

**Cell culture and transfection**

Both transiently and stably transfected human embryonic kidney (HEK293) cells were used in this study. Cell culture, plasmid construct, and transfection procedures are described in the supplemental Methods.

**Measurement of surface protein expression**

Platelet surface glycoproteins and thrombin-induced P-selectin expression were measured by flow cytometry with an Accuri C6 flow-cytometer (BD Biosciences), with data analyzed by FACSCalibur.

P2Y1 and P2Y12 surface receptor expression was assessed by ligand binding using [3H]-2MeSADP, as previously described. Tagged surface receptors levels were assessed in HEK293 cells by enzyme-linked immunosorbent assay, as described, and receptor recycling was measured by flow cytometry as described. Details of the procedures are given in the supplemental Methods.
Coimmunoprecipitation and immunoblot detection
P2Y_{12}R and tetherin/BST-2 interaction was assessed in both cell lines and human platelets by coimmunoprecipitation followed by western blot analysis, as previously described\textsuperscript{23} and are described in the supplemental Methods.

Assessment of cAMP accumulation in mouse platelets and transfected HEK293 cells
Adenosine diphosphate (ADP)–induced inhibition of forskolin (1 \textmu M)–stimulated cyclic adenosine monophosphate (cAMP) accumulation was performed in washed mouse platelets or in transiently transfected HEK293 cells, as previously described.\textsuperscript{22,26} Data are expressed as the percentage of inhibition of forskolin-stimulated adenylyl cyclase.

Calcium mobilization assay
ADP-induced calcium mobilization was measured in mouse platelets by using the Fura-2 LR/AM calcium indicator in a process described in the supplemental Methods.

Immunofluorescence microscopy
The methods used for preparation of samples (both HEK293 cells and mouse platelets) for subsequent immunofluorescence microscopy are given in detail in the supplemental Methods.

Confocal imaging of platelets or transfected HEK293 cells was performed with a Leica SP8 confocal microscope (Leica Microsystems). Excitation was provided by either a 488-nm (green fluorescent protein [GFP]) or 561-nm (mCherry) laser, and all images were acquired with a 63× 1.4 numeric aperture (NA) oil-immersion objective.

Fluorescence lifetime imaging (FLIM) was performed on a Leica TCS SP8 confocal microscope equipped with a PicoHarp 300 time-correlated, single-photon–counting module (PicoQuant). A white-light laser with a repetition rate of 20 MHz was set at 488 nm for GFP excitation. Images were acquired with a 63× 1.4 NA oil-immersion objective with GFP fluorescence collected from 495 to 530 nm, and data were fitted using FLIMfit.\textsuperscript{26}

Live-cell total internal reflection fluorescence (TIRF) microscopy was performed with a Leica AM TIRF MC system at 37°C in 5% CO\textsubscript{2}. Excitation was provided by a 488-nm (GFP) or 561-nm (mCherry) laser, and all images were acquired with a 100× 1.47 NA, oil-immersion TIRF microscope objective. Images were captured at 3-second intervals for 1 minute.

Fluorescence recovery after photobleaching (FRAP) was performed on a Leica SP8 confocal microscope. Excitation was provided by either a 488-nm (GFP), a 561-nm (mCherry), or a 633-nm (Alexa 647) laser. Images were acquired with a 100× harmonic compound, plan, apochromat, oil-immersion objective. Photobleaching was performed after 10 prebleaching scans by illuminating a circular 2-\textmu m-diameter spot with the 561-nm laser set to 100% for 5.175 seconds. Images of fluorescence recovery were captured in successive intervals of 1.725 seconds for a duration of 260 seconds. Fluorescence recovery was quantified using ImageJ. The detailed procedures for these imaging methods are available in supplemental Methods.

Modeling
A variant GPI anchor of tetherin/BST-2 was constructed with a palmitoyl and oleoyl phospholipid tail.\textsuperscript{27} The missing residues from the C terminus of tetherin/BST-2 (Protein Database no. 3NWJ) were built in a helical conformation, and the GPI anchor was attached via a helical group of Ser 160. The palmitoyl and oleoyl tails of the GPI anchor were packed against the P2Y_{12}R structure on the face presented by the transmembrane helices I, VI, and VII of P2Y_{12}R in the positions occupied by oleoyl glycerol in the crystal structure (Protein Database no. 4PX2).\textsuperscript{29,28} For clarity, only a single GPI anchor attached to tetherin/BST-2 is shown. The modeling and image generation were performed with Chimera (1.11.2).

Bioluminescence resonance energy transfer measurement
Complementary Rluc-II-Gxix1 and GFP10-Gx12 constructs were used to measure G protein activation downstream of receptor stimulation, as described previously\textsuperscript{30} and detailed in the supplemental Methods.

Statistical analysis
Data analyses and determinations of statistical significance were performed with Prism 7.0 software (GraphPad) and are described in the supplemental Methods.

Results
Does tetherin/BST-2 affect P2Y_{12}R function in platelets?
Platelets express several surface receptors, including the P2Y_{12}R, which necessitates their association with membrane microdomains for optimal function.\textsuperscript{5–7} We hypothesized that tetherin/BST-2, an established regulator of membrane microdomain organization, could regulate the activity of these receptors. We initially established that tetherin/BST-2 is expressed in both human and mouse platelets by both reverse transcription–polymerase chain reaction (RT-PCR; Figure 1A) and western blot analysis (Figure 1B). Importantly, tetherin/BST-2 expression was undetectable in tetherin/BST-2−/− mouse platelets, validating both primer and antibody specificity (Figure 1A). There were no obvious differences between wild-type (WT) and tetherin/BST-2−/− mice in major hematologic parameters, including platelet count (supplemental Figure 1A), mean platelet volume, and platelet distribution width (data not shown); the expression of surface glycoproteins (CD41, glycoprotein VI [GPVI], GPI-bx, and PAR-4; supplemental Figure 1B); and the levels and patterns of oligomers, dimers, and monomers of the P2Y_{12}R in platelets (supplemental Figure 1C).

Ligand binding experiments using [3H]-2MeSADP revealed comparable expression of P2Y_{12}R in WT vs tetherin/BST-2−/− platelets (790 ± 59 and 864 ± 83 P2Y_{12}R per platelet in WT and tetherin/BST-2−/− platelets).

Given the therapeutic relevance of and our longstanding interest in P2Y_{12}R biology,\textsuperscript{22,23,26,31} we first focused on whether tetherin/BST-2 regulates P2Y_{12}R function. We observed that ADP-stimulated platelet aggregation was significantly enhanced in tetherin/BST-2−/− vs littermate control WT mouse platelets (example aggregation traces in platelet rich plasma [PRP; Figure 1C]) and washed platelets, with averaged data showing the percentage of maximum aggregation in washed platelets [Figure 1D]). Intriguingly, in washed platelets at
Figure 1. Tetherin/BST-2 negatively regulates P2Y₁₂R activities in both platelets and cell lines. (A) PCR and RT-PCR were used to genotype mice. RT-PCR was performed on total RNA isolated from BST²+/+ and tetherin/BST-2⁻/⁻ mouse platelets, with primers specific for glyceraldehyde-3-phosphate dehydrogenase or tetherin/BST-2.
a higher ADP concentration (10 μM), platelet aggregation was not affected in tetherin/BST-2−/− mice, indicative that the effect of tetherin/BST-2 knockdown was surmountable. To further explore this point, we assessed ADP-stimulated platelet signaling. Given that ADP activates both the Gq-coupled P2Y1 and Gi-coupled P2Y12Rs to stimulate platelet aggregation, we assessed signaling outputs downstream of each receptor. ADP-induced inhibition of forskolin-stimulated adenyl cyclase was significantly enhanced in tetherin/BST-2−/− platelets, with an increase in both the maximum response and leftward shift of the concentration-response curve (Figure 1E). In contrast, there was no change in ADP-induced intracellular calcium responses, which was largely mediated by the G-coupled P2Y1R, in WT vs tetherin/BST-2−/− platelets (Figure 1F). These data suggest that tetherin/BST-2 selectively negatively regulates P2Y12R activity in mouse platelets.

Pilot experiments in human platelets next examined whether changes in tetherin/BST-2 expression had the potential to affect ADP-stimulated platelet receptor function. ET is a classic BCR-ABL1− myeloproliferative neoplasm characterized by overproduction of mature platelets accompanied by an increased risk of thrombosis with a risk of major thrombotic events in patients that ranges from 10% to 29%.32 IFN-α therapy is an approach to treatment of ET that represses the proliferation of hematopoietic progenitors, primarily to control platelet counts, thereby reducing the risk of thrombosis without increasing the tendency to bleed.33 Notably, IFN treatment upregulates tetherin/BST-2 expression in various cell types across multiple species, including humans.34 We therefore assessed platelet tetherin/BST-2 levels and ADP-induced platelet aggregation in 4 enrolled patients with ET before and after IFN therapy (supplemental Figure 2). Because IFN treatment decreases the number of platelets, we normalized our platelet count (3.0 × 108 cells per milliliter) in our subsequent experiments, thereby ensuring changes in platelet reactivity did not occur because of changes in the number of platelets. IFN therapy increased tetherin/BST-2 expression (supplemental Figure 2A, representative blot from 1 patient; supplemental Figure 2B, quantified data across patients). Along with this increase in tetherin/BST-2 expression, IFN treatment significantly attenuated ADP-stimulated platelet reactivity (supplemental Figure 2C, representative aggregation traces; supplemental Figure 2D, across patients). Although preliminary in nature, these data suggest that tetherin/BST-2 negatively regulates ADP-stimulated platelet activity in humans.

To further explore tetherin/BST-2-dependent regulation of the P2Y12R we expressed both proteins in HEK293 cells. HEK293 cells were specifically used, as they are tetherin/BST-2 null,15 enabling the clear establishment of the effects of tetherin/BST-2 expression on receptor function. Notably, tetherin/BST-2 expression significantly reduced downstream P2Y12R activity with reductions in both ADP-stimulated inhibition of adenyl cyclase activity (Figure 1G) and ERK1/2 phosphorylation (Figure 1H, representative blot; Figure 1I, quantified data). TIRF microscopy was used to measure changes in mCherry-HA-P2Y12 surface expression in HEK293 cells transiently cotransfected with mCherry-HA-P2Y12R and either BST-2-GFP or GFP vector control (Figure 1J). As in mouse platelets, changes in tetherin/BST-2 expression did not significantly affect P2Y12R surface expression (Figure 1J). These data further confirmed that tetherin/BST-2 negatively regulates P2Y12R activity.

**Does tetherin/BST-2 colocalize and functionally interact with the P2Y12R?**

Initial confocal microscopy in mouse platelets spread on fibrinogen revealed that tetherin/BST-2 colocalized with the P2Y12R (representative images Figure 2A, with image analysis showing pixel intensity histograms of gray scale images for both the green and red channels (Figure 2B) and colocalization (Figure 2D). A more detailed understanding of tetherin/BST-2 colocalization was provided by experiments on HEK293 cells coexpressing tetherin/BST-2-GFP and mCherry-HA-tagged P2Y12Rs. Confocal microscopy indicated that these proteins predominantly associated at the cell membrane (Figure 2C, representative images; Figure 2D, imaging analysis). The agonist dependence of any potential receptor and tetherin/BST-2 interaction was then assessed by immunoprecipitation, first in HEK293 cells and then in human platelets. Cells were treated with ADP (20 μM; 0, 5, 30, and 60 minutes) solubilized, and anti-HA immunoprecipitation was performed. Subsequent immunoblot analysis revealed a specific association of P2Y12R with tetherin/BST-2, which was significantly attenuated by receptor activation (Figure 2E-F). Washed human platelets were treated with

---

**Figure 1. (continued)** (B) Washed platelets from humans or BST-2−/− and BST-2+/+ mice were solubilized and immunoblotted with tetherin/BST-2 or tubulin-specific antibodies. Data are representative of at least 4 independent experiments. (C-D) ADP-stimulated platelet aggregation was significantly enhanced in BST-2−/− vs BST-2+/+ mice in either platelet-rich plasma (PRP) (C) or washed platelets (D). Representative traces of platelet aggregation in PRP or washed platelets are shown and are representative of 5 independent experiments. Data from washed platelets were quantified and expressed as maximum platelet aggregation (right). Data represent mean ± standard error of the mean (SEM) of 5 independent experiments. Maximum platelet aggregation was significantly enhanced in BST-2−/− vs BST-2+/+ mice. *P < .05; 2-tailed Student t test. (E) P2Y12R activity in BST-2−/− vs BST-2+/+ mouse platelets, as assessed by inhibition of forskolin (1 μM; 10 minutes)-induced cAMP production by ADP (0.1 nM-100 μM; 10 minutes). Data are means ± SEM of 4 independent experiments with ADP-stimulated inhibition of adenyl cyclase activity significantly enhanced in BST-2−/− vs BST-2+/+ mouse platelets (2-way analysis of variance [ANOVA]; P < .01). (F) ADP (0.1-10 μM)-stimulated calcium responses were unchanged in BST-2−/− vs BST-2+/+ mouse platelets. Data are expressed as peak calcium responses (ratio of 340 nm/380 nm readings with Fura-2) and represent the mean ± SEM of 3 independent experiments. (G-I) ADP-induced inhibition of forskolin-stimulated cAMP production and ERK1/2 activation were assessed in cells transiently cotransfected with mCherry-HA–tagged P2Y12R and either tetherin/BST-2-GFP or GFP control vectors. (G) In P2Y12R-expressing cells, ADP-induced (0.1 nM-100 μM; 10 minutes) inhibition of forskolin-stimulated (1 μM; 10 minutes) cAMP production was significantly attenuated by tetherin/BST-2-GFP overexpression. P < .01; 2-way ANOVA. Data are the mean ± SEM of 4 independent experiments. (H) Activity of ADP (20 μM)-stimulated ERK1/2 activation was also assessed by immunoblot analysis with a p-ERK specific antibody. Total ERK and α-tubulin served as protein-loading controls. (H) Representative blots of at least 4 independent experiments. (I) Data expressed as p-ERK levels normalized to total ERK. Mean ± SEM; n = 4. P2Y12R-stimulated ERK activity was significantly attenuated by tetherin/BST-2-GFP overexpression (P < .05; 2-way ANOVA). (J) Fluorescence intensity profile of mCherry-HA-P2Y12R surface expression taken from TIRF microscopy images of HEK293 cells coexpressing tetherin/BST-2-GFP or GFP control (n = 6 cells over the course of 6 independent experiments).
Figure 2. Colocalization and interaction of tetherin/BST-2 with P2Y12R. Tetherin/BST-2 colocalized with the P2Y12R in (A-B,D) mouse platelets and (B-C) HEK293 cells. (A) Representative confocal images of permeabilized mouse platelets spread on fibrinogen and treated with rat anti-mouse tetherin/BST-2 and rabbit anti-P2Y12, followed by anti-rat Alexa 488 (green)– and anti-rabbit Alexa 546 (red)–conjugated secondary antibodies. Bar represents 10 μm. (B) Pixel intensity histograms of gray scale images (A; bottom) corresponding to output from green and red channels (A; top). (C) HEK293 cells were transiently transfected with tetherin/BST-2-GFP alone or with either mCherry or mCherry-HA-P2Y12R. Fixed cell samples were prepared for subsequent confocal microscopy. Representative confocal images of HEK293 cells coexpressing BST-2-GFP (green) and mCherry (red; top), GFP and mCherry-P2Y12-HA (middle), or BST-2-GFP and mCherry-P2Y12-HA (bottom). Bar represents 1 μm. Images from panels A and C underwent subsequent quantitative analysis (C; n = 16 for platelet and n = 22 for HEK293 cells, across 3 independent experiments). (D) Pearson’s correlation coefficients (PCCs) in either platelets or in the whole cell vs the membrane or cytoplasm of the cell. The PCCs were significantly higher in membranes vs either the whole cell or...
ADP (10 μM; 30 minutes) and lysed, and anti-P2Y12R immunoprecipitation was performed. Subsequent immunoblot analysis revealed a specific association of the P2Y12R with tetherin/BST-2, which as in the cell lines, was significantly attenuated by receptor activation (Figure 2G).

To further assess how P2Y12R activation affected interaction with tetherin/BST-2, we used quantitative Förster resonance energy transfer (FRET)-based FLIM (FRET-FLIM). In these assays, we assessed fluorescence lifetime in HEK293 cells transiently cotransfected with tetherin/BST-2-GFP and either mCherry-HA-P2Y12R or mCherry vector control. Given that our data suggested that the P2Y12R predominantly colocalized with tetherin/BST-2 at the plasma membrane, our FLIM images were segmented into the plasma membrane (Figure 3A) and cytoplasm (supplemental Figure 3). We focused on the plasma membrane section (Figure 3A). Coexpression of tetherin/BST-2-GFP and mCherry-HA-P2Y12R led to a significant reduction of fluorescence life of the FRET donor in the plasma membrane compared with tetherin/BST-2-GFP alone or the tetherin/BST-2-GFP + mCherry control (Figure 3A-B; representative images and pooled data, respectively). These data further demonstrate that the P2Y12R is in close proximity to and most likely directly interacts with tetherin/BST-2. Notably, receptor activation by ADP (20 μM; 5, 30, and 60 minutes) increased donor life. This effect was reversed by removal of ADP by treatment with apyrase (5 minutes; 1 U/mL; 60 minutes with apyrase; Figure 3B). These data again suggest that receptor activation reduced association with tetherin/BST-2. To further understand the mechanism of agonist-mediated impaired association of P2Y12R with tetherin/BST-2, single-cell analysis of the intensity of intracellular tetherin/BST-2-GFP and mCherry-HA-P2Y12R was undertaken (Figure 3C-E). Cell images captured before FLIM were segmented for analysis (Figure 3C). The intracellular intensity of P2Y12R increased after application of the agonist. The increased intensity was reversed after removal of ADP by addition of apyrase (Figure 3D). Tetherin/BST-2 levels meanwhile remained relatively constant (Figure 3E) indicating that receptor activation promoted membrane dissociation of P2Y12R-tetherin/BST-2 complex, with subsequent receptor internalization.

**Tetherin/BST-2-dependent regulation of P2Y12R surface expression**

ADP-induced P2Y12R dissociation with BST-2/tetherin and subsequent internalization were further confirmed with TIRF microscopy by measuring fluorescence changes of BST-2-GFP and mCherry-HA-P2Y12R in 150-nm penetration depth of the membranes of cells transiently cotransfected with mCherry-HA-P2Y12R and either BST-2-GFP or GFP vector control (Figure 4A-D). There was a gradual but significant agonist-stimulated reduction in P2Y12R surface levels over time (Figure 4A-C), whereas tetherin/BST-2-GFP surface expression remained constant (Figure 4A-B,D). Furthermore, in cells coexpressing P2Y12R and tetherin/BST-2-GFP, agonist-stimulated loss of surface receptors was attenuated (Figure 4C).

The P2Y12R is efficiently and rapidly recycled to the cell surface in platelets. To investigate whether these tetherin/BST-2-regulated changes in surface P2Y12R levels are caused by a defect in receptor internalization or a potentiation of receptor recycling, a recycling assay was used with FLAG-tagged-P2Y12R. In this assay, the receptor is prelabeled, with a calcium sensitive FLAG antibody (M1) and agonist added to stimulate receptor internalization. The surface-bound FLAG antibody is then stripped by a calcium-free wash, and the recycling of internal FLAG-P2Y12R is monitored by fluorescence-activated cell sorting after removal of the agonist. FLAG-P2Y12R efficiently recycled to the cell surface, with tetherin/BST-2-GFP expression having no effect, suggesting that tetherin/BST-2 had little effect on the recycling of P2Y12R-Rs (Figure 4E). Therefore, tetherin/BST-2 is the likely regulator of P2Y12R internalization.

In agreement with these experiments in HEK293 cells, ligand-binding experiments in mouse platelets showed that agonist-induced P2Y12R surface loss was potentiated in tetherin/BST-2−/− mice (Figure 4F). Meanwhile, agonist-induced P2Y1R surface loss in mouse platelets was unaffected by changes in tetherin (Figure 4G). These data further confirm that tetherin/BST-2 selectively and negatively regulates specific receptors.

**What is the molecular basis of the tetherin/BST-2: P2Y12R interaction?**

We next explored the molecular determinants of tetherin/P2Y12R interaction. The recently solved crystal structure of the P2Y12R revealed significant levels of cholesterol packed around the receptor that are suggested to help pack the receptor in higher oligomers. Molecular modeling of the P2Y12R with tetherin/BST-2 revealed the potential for the C-terminal GPI anchor of tetherin/BST-2 to displace this cholesterol, potentially affecting receptor function (Figure 5A-B). We therefore explored the potential importance of the GPI anchor of tetherin/BST-2 in HEK293 cells by coexpressing FLAG-tagged P2Y12R with either full-length HA-tagged WT tetherin/BST-2 (WT-HA) or a series of previously described tetherin/BST-2 deletion constructs (Figure 5C). These included truncations lacking either the N-terminal region (∆N-HA) or the GPI anchor (∆GPI-HA) of tetherin. A further construct (C3A-HA), in which 3 critical cysteine residues that stabilize tetherin/BST-2 dimer formation through disulfide bonds are changed to alanines, was also tested. FLAG-P2Y12R was immunoprecipitated with anti-FLAG affinity
Figure 3. Tetherin/BST-2 interacts directly with the P2Y12R. HEK293 cells were transiently transfected with tetherin/BST-2-GFP (FRET donor) alone or with either mCherry or mCherry-HA-P2Y12R (FRET acceptor). Cells coexpressing tetherin/BST-2 and P2Y12R were stimulated with ADP (20 μM; 0-60 minutes) or with ADP (20 μM; 60 minutes), followed by the addition of apyrase (1 U/mL) for 5 minutes. Fixed cell samples were prepared for subsequent microscopy. (A) Representative fluorescence intensity (gray scale images, top) and corresponding intensity-weighted (pseudocolor, bottom) images of cell membranes at selected time points of measurement. (B) Fluorescence lifetime measurements of tetherin/BST-2-GFP from cell membrane regions showing association of P2Y12R with tetherin/BST-2. Coexpression of tetherin/BST-2-GFP (donor) with mCherry-HA-P2Y12R (acceptor) significantly reduced donor vs mCherry life (\( * P < .05; \) Student t test) indicative of protein proximity. Addition of ADP (5, 30, and 60 minutes) significantly increased donor life vs the non–agonist-treated control (\( \$ P < .05; \) Student t test) or after apyrase removal of ADP (\( \varepsilon P < .05; \) Student t test). (C-E) Agonist-induced changes in P2Y12R and tetherin/BST-2 intracellular expression were assessed, and the data were normalized and expressed as a percentage of whole-cell fluorophore intensity. (C) Cell images captured before FLIM were segmented in CellProfiler by using a semiautomatic approach. Identified objects were subsequently reduced in size by 10% to produce complementary masks to define the cell edge and central regions. ADP treatment had no effect on tetherin/BST-2 intracellular expression (D), but promoted a significant increase in intracellular accumulation of the P2Y12R vs non–agonist-treated control (\( * P < .05; \) Student t test) or after apyrase removal of ADP (\( \varepsilon P < .05; \) Student t test; E). (B,D-E) Data points represent a single cell (n > 12 per transfection condition) pooled across 3 independent experiments with line and error bars representing means ± standard error of the mean.
Figure 4. Tetherin/BST-2 negatively regulates P2Y12R internalization in both cell lines and mouse platelets. (A) Representative live TIRF microscopy images of HEK293 cells coexpressing mCherry-HA-P2Y12R (red) and either GFP control (green; top) or tetherin/BST-2-GFP before (green; middle) and after agonist stimulation (ADP; 20 μM; 60 minutes; green; bottom). (B) Fluorescence intensity profiles from lines shown in images from panel A assessing either mCherry (receptor) or GFP (either control or tetherin/BST-2) surface expression. (C-D) A time course series (0-60 minutes) of the intensity profiles was assessed (n = 6 cells over the course of 6 independent experiments), and the ADP-stimulated change in surface mCherry-HA-P2Y12R (C) or tetherin/BST-2-GFP (D) was quantified (percentage change after agonist stimulation; mean ± standard error of the mean [SEM]). (E) Assessment of FLAG-P2Y12R recycling by flow cytometry. Receptor-expressing cells prelabeled with anti-FLAG(M1)-FITC were stimulated with ADP (20 μM; 60 minutes). Surface antibody and ADP were removed by washing with a Ca2+-free buffer containing apyrase (0.2 U/mL). P2Y12R
gel and HA-tetherin/BST-2 interaction assessed by western blot. As expected, the P2Y₁₂R associated with WT-HA. Interestingly, only the removal of the GPI anchor of tetherin/BST-2 was found to disrupt receptor interaction. To exclude the possibility that the loss of interaction was due to minimal ΔGPI-HA mutant surface expression, we assessed receptor interaction with a tetherin/BST-2 construct in which the GPI anchor was replaced by the CD8α transmembrane domain (ΔGPI-CD8α-HA), to mimic the topology of WT tetherin/BST-2 at the cell surface.¹⁵ Again ΔGPI-CD8α-HA did not interact with P2Y₁₂R. The GPI anchor of tetherin/BST-2 therefore is critical for receptor interaction. Given that the ΔGPI-CD8α-HA construct is unlikely to be localized to membrane microdomains,³⁶ we suggest that the GPI anchor is critical for tetherin/BST-2 localization in P2Y₁₂R-containing membrane microdomains and for direct interaction with P2Y₁₂R.

To further explore whether the GPI anchor is necessary for tetherin/BST-2 regulation of P2Y₁₂R signaling, we monitored receptor/G-protein activation by a standard bioluminescence resonance energy transfer (BRET)—based approach that measures agonist-stimulated changes in Goα/βi disassociation by the functionally validated BRET pair Rluc-II-Gqi-1 and GFP10-Gγ2.³⁶ Upon receptor activation, Rluc-II-Gqi-1 and GFP10-Gγ2 rapidly disassociated, leading to a decrease in BRET signal (Figure 5D). As expected, tetherin/BST-2 expression significantly reduced P2Y₁₂R-stimulated changes in G-protein activation (Figure 5D). Expression of either ΔGPI-HA or ΔGPI-CD8α-HA constructs had no effect on P2Y₁₂R activity, confirming the requirement of the GPI anchor of tetherin/BST-2 to regulate receptor function.

Our molecular modeling suggested that the GPI anchor of tetherin/BST-2 could displace cholesterol, which influences membrane integrity and modulates membrane fluidity.⁴⁻³ Could the potential displacement of this cholesterol affect P2Y₁₂R activity by changing local membrane fluidity and limit the conformational freedom of the receptor? To investigate, we performed FRAP experiments to examine P2Y₁₂R membrane mobility inside and outside of membrane microdomains in the absence or presence of tetherin/BST-2. We used cholera toxin subunit B (CT-B) conjugated to Alexa Fluor 647 which binds to the pentasaccharide chain of the GPI anchor of tetherin/BST-2. We used cholera toxin subunit B (CT-B) conjugated to Alexa Fluor 647 which binds to the pentasaccharide chain of the GPI anchor of tetherin/BST-2 to examine P2Y₁₂R membrane mobility inside and outside of membrane microdomains. The collagen-receptor GPVI³⁸ and the G-protein–coupled TP receptor³⁷ have been shown to be associated with membrane microdomains, whereas there is evidence that the thrombin-stimulated PAR4 receptor associates with P2Y₁₂.¹¹ Notably, platelet aggregation was enhanced in tetherin/BST-2⁻/⁻ platelets after activation of the PAR4 (Figure 6A, representative trace), TP (Figure 6B, representative trace) or GPVI receptor (Figure 6C, representative trace; Figure 6D, mean data for all agonists showing the percentage of maximum aggregation vs littermate control W) mouse platelets). We also assessed platelet-dense granule secretion by measuring ATP release. The level of secretion of all 3 receptors in tetherin/BST-2⁻/⁻ platelets was also enhanced (Figure 6A-C, representative traces, bottom; Figure 6E, quantified data). Enhanced agonist-stimulated ATP secretion was not related to increased total levels of ATP in secretory granules in tetherin/BST-2⁻/⁻ platelets (supplemental Figure 1D).

Thrombin- and GPVI-dependent platelet activation is in part related to the stimulation of P2YRs after secretion.³⁹ We therefore asked whether the enhancement of both CRP- and thrombin-stimulated platelet aggregation and ATP secretion would be maintained if we antagonized the P2Y₁₂R. As expected, antagonism of the P2Y₁₂R with ARC66096 (10 μM) completely abolished CRP (0.4 μM)-stimulated platelet aggregation and secretion (data not shown) and partially reduced thrombin-stimulated platelet aggregation (Figure 6A, example trace, top; Figure 6D, quantified data) and secretion (Figure 6A, example trace, bottom and Figure 6E, quantified data). Importantly, thrombin-stimulated platelet aggregation and secretion in the presence of ARC66096 continued to be enhanced in tetherin/BST-2⁻/⁻ platelets. We also assessed thrombin-induced P-selectin exposure at the platelet surface to study whether tetherin modulates platelet α-granule secretion. There was a significant increase in thrombin-stimulated P-selectin presented at the platelet surface in tetherin/BST-2⁻/⁻ vs WT platelets (Figure 6E). Therefore, in summary, our experiments revealed tetherin/BST-2 to be a negative regulator of the activity of a series of putative membrane-microdomain–localized receptors.

**Figure 4.** (continued) recycling was then monitored by flow cytometry. Data represent percentage of recycled P2Y₁₂R (*P < .05; 1-way analysis of variance [ANOVA]). (F-G) P2Y₁₂, but not P2Y₁₃R internalization, was negatively regulated by tetherin/BST-2 in mouse platelets. DST-2⁻/⁻ and DST-2⁻/⁺ mouse platelets were stimulated with ADP (10 μM). P2Y₁ and P2Y₁₂ surface receptor levels were measured in fixed, washed platelets, with[³²H]-2MeSADP (100 nM) in the presence of either the P2Y₄R antagonist A3P5P (1 mM) or the P2Y₁₃R antagonist AR-C49931MX (1 μM). Data are expressed as a percentage of surface receptor and represent means ± SEM of 3 independent experiments. P2Y₁₂, but not P2Y₁₃R surface loss was potentiated in DST-2⁻/⁻ vs DST-2⁻/⁺ mouse platelets (*P < .05; 2-way ANOVA).
Figure 5. The GPI anchor of tetherin/BST-2 is needed to regulate P2Y₁₂R function. (A) An overlay of the P2Y₁₂R crystal structures: antagonist bound (wheat, 4NTJ) and agonist bound (cyan, 4PXZ). Protein structures are shown as ribbons, and cholesterol (wheat) and 1-oleoyl-R-glycerol (cyan) are shown in space-filling representations. TM-helices binding these lipids are labeled I, VI, and VII. (B) A model of the tetherin/BST-2-GPI interaction with P2Y₁₂R. C-terminal part of tetherin/BST-2, magenta ribbon; GPI anchor in space-filling representations with the lipid tails in the membrane packed against agonist-bound P2Y₁₂R, shown as cyan ribbon. Molecular modeling showing potential interaction between tetherin/BST-2 and the P2Y₁₂R. (C) The GPI anchor of tetherin/BST-2 is necessary for P2Y₁₂R interaction. HEK293 cells were transfected with...
Discussions

Membrane microdomains play an established role in receptor biology. For example, in platelets, the P2Y12 and TP receptors, which amplify platelet activation when stimulated, are both associated with membrane microdomains. The integral membrane protein tetherin/BST-2, an established restriction factor for enveloped viruses, stabilizes membrane microdomains and alters both lipid and protein distribution within the plasma membrane. In this study, we showed, for the first time, a fundamental role of this ubiquitously expressed protein in negatively regulating platelet receptor function. Tetherin/BST-2 regulates the activity of several receptors, with the function of P2Y12, PAR, TP, and GPVI receptors enhanced in tetherin/BST-2 mice. Notably, this effect of tetherin is receptor specific, with no changes in the function of receptors (eg, P2Y1R) that are not found in these membrane microdomains. Furthermore, in relation to cardiovascular disease, we demonstrated in patients that IFN treatment upregulates platelet expression of tetherin/BST-2 with an accompanying reduction in platelet reactivity.

Our detailed molecular experiments demonstrated a complex mode of action of tetherin/BST-2 that in part requires the C-terminal GPI anchor of the protein and involves changes in surface receptor mobility. Biochemical fractionation, receptor immunoprecipitation, and confocal imaging techniques demonstrated that there was constitutive association between the P2Y12R and tetherin/BST-2 in both cells and, importantly, in human platelets. Through a FRET-FLIM approach, we demonstrated that surface association between receptor and tetherin/BST-2 is reversibly reduced in the presence of agonist. After disassociation, tetherin/BST-2 remained at the cell surface, whereas P2Y12R was internalized. We have previously established that the P2Y12R interacts with a range of intracellular binding partners, after phosphorylation of G-protein-coupled receptor kinase, which coordinates receptor internalization via a clathrin-mediated pathway. Detailed further study is now needed to understand the relationship between tetherin/BST-2 and its effect on P2Y12R interaction with other regulatory binding partners.

Results of molecular modeling experiments suggested that the GPI anchor of tetherin/BST-2 plays a role in receptor interaction, with 3 TM helices (I, VI, and VII) of the P2Y12R potentially involved in interaction with the GPI anchor. Intriguingly, these are the same helices that showed the most perturbation between the agonist- and antagonist-bound crystal structures. We speculate, therefore, that tetherin/BST-2 modulates the conformational freedom of the P2Y12R to perturb agonist responsiveness. However, it should be kept in mind that these regions of the P2Y12R are involved in receptor dimerization in the antagonist-bound crystal structure, although we have no evidence of significant changes in levels of receptor oligomerization.

The key role of the GPI anchor of tetherin/BST-2 in receptor interaction was confirmed in mutagenesis experiments. Could the GPI anchor of tetherin displace cholesterol from membrane microdomains to affect P2Y12R activity? Cholesterol depletion from cell membranes is known to attenuate P2Y12R activity. Notably, the crystal structure of the P2Y12R indicates that cholesterol packs around the receptor to maintain conformational integrity. However, given that the GPI anchor is also necessary for effective localization of tetherin/BST-2 to membrane microdomains, we can at this time only speculate that displacement of cholesterol by the GPI anchor of tetherin/BST-2 is a direct regulator of P2Y12R activity.

Intriguingly, we found that tetherin/BST-2 expression limited agonist-stimulated lateral diffusion of the P2Y12R within membrane microdomains. Expression of high-order oligomeric complexes containing the P2Y12R in membrane microdomains is necessary for effective receptor signaling. Given that agonist-stimulated internalization is necessary to maintain P2Y12R signaling, does tetherin/BST-2 limit the movement of non-desensitized receptors into or desensitized receptors out of membrane microdomains? Two studies have established that the lateral distribution and mobility of receptors in the membrane plane bring signaling partners efficiently into transient or stable contact. Various models of GPCR membrane organization and associated trajectories have been suggested with receptors that freely diffuse over long distances in the membrane. However, their movement is also restricted within membrane microdomains. Further detailed study is now needed to investigate movement of P2Y12Rs and whether the
formation by tetherin/BST-2 of a physical barrier or picket fence linked to the underlying actin cytoskeleton at the perimeter of membrane microdomains is critical for function.

Our experiments in mouse platelets and cell lines have therefore established tetherin/BST-2 as a regulator of receptor function. Previous studies have demonstrated that patients who receive IFN, which is used in the treatment of a variety of clinical conditions, including ET, leads to an upregulation of tetherin/BST-2 expression in various cell types.13 Intriguing pilot studies in human platelets showed that IFN treatment of patients with ET increased tetherin/BST-2 expression was accompanied by decreased ADP-stimulated platelet reactivity. ET is characterized by overproduction of mature platelets and an increased risk of thrombosis.32 The goals of cytoreductive therapy for ET are primarily to reduce the risk of thrombosis without increasing the tendency toward bleeding and to minimize the risk of progression to myelofibrosis or acute leukemia.32 The results of our pilot study suggest that IFN reduces risk of thrombosis, not only by decreasing the number of platelets, but also by directly attenuating their function. There are reported reductions in platelet reactivity after administration of IFN for the treatment of melanoma44 and hepatitis C,45 with the suggestion that reductions in platelet reactivity limit platelet participation in disease progression (ie, by limiting the inflammatory process involved in hepatitis C or by reducing or preventing the formation of melanoma metastases). In addition, given the effects on platelet reactivity, it should be noted that IFN treatment could have implications in the event of accidental injury or elective surgery. Clearly, this notion requires further extensive study, well beyond the scope of this current work.

In summary, these findings have broad implications for our understanding of platelet receptor signaling from the membrane microdomain, indicating that tetherin/BST-2 plays a key role in regulating output from these sites and may represent a useful therapeutic target for regulating platelet receptor and therefore platelet reactivity.

Acknowledgments

This work was supported by British Heart Foundation Project Grants PG/13/94/30594 (X.Z.) and PG/17/62/33190 (J.K.); Chinese Academy of Medical Sciences (CAMS) Key Laboratory of Gene Therapy for Blood Disease (2017PT31047, China); and CAMS Initiative for Innovative Medicine (2016-12M-1-018; 2017-12M-1-015, China).
Authorship

Contribution: X.Z. designed and performed the research, analyzed and interpreted the data, and wrote the manuscript; D.A. designed the FRET-FLM and FRAP assays and analyzed and interpreted the data; T.S. designed the clinical experiments and analyzed and interpreted the data; J.L.H. developed the calcium assay and collected and analyzed the data; J.K., K.O., R. Seager, R.A., C.M.M., and D.P. analyzed and interpreted the data; C.M.W. and Y.L. performed the in vivo thrombus formation experiment and collected and analyzed the data; R. Sessions designed the molecular modeling experiments and analyzed and interpreted the data; S.C. performed the statistical analyses; A.L. developed the TIRF experiment; L.Z. designed and supervised the clinical experiments and analyzed and interpreted the data; A.W.P. and G.B. jointly supervised the research, analyzed and interpreted the data, and revised the manuscript; S.J.M. designed and supervised the research, analyzed and interpreted the data, and was a joint author of the manuscript; and all authors critically revised the manuscript and approved the final version.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

ORCID profiles: S.C., 0000-0003-3565-0479; R. Seager, 0000-0002-8904-5795; A.W.P., 0000-0002-0868-297X.

Correspondence: Stuart J. Mundell, University of Bristol, Pharmacology and Neuroscience, School of Physiology, Biomedical Sciences Building, University Walk, Bristol BS8 1TD, United Kingdom; e-mail: s.j.mundell@bristol.ac.uk.

References

1. Yeung J, Li W, Holinstat M. Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases. Pharmacol Rev. 2018;70(3):526-548.

2. Stocker TJ, Ishikawa-Ankerhold H, Massberg S, Schulz C. Small but mighty: Platelets as central effectors of host defense. Thromb Haemost. 2017;117(4):851-861.

3. Jacobson K, Mountsen OG, Anderson RG. Lipid rafts: at a crossroad between cell biology and physics. Nat Cell Biol. 2007;9(1):7-14.

4. Lee MY, Ryu JM, Lee SH, Park JH, Han HJ. Lipid rafts play an important role for maintenance of embryonic stem cell self-renewal. J Lipid Res. 2010;51(8):2082-2089.

5. Moscardo A, Vallés J, Latorre A, Santos MT. The association of thromboxane A2 receptor with lipid rafts is a determinant for platelet functional responses. FEBS Lett. 2014;588(17):3154-3159.

6. Quinton TM, Kim S, Jin J, Kunapuli SP. Lipid rafts are required in Galphai(i) signaling downstream of the P2Y12 receptor during ADP-mediated platelet activation. J Thromb Haemost. 2005;3(8):1036-1041.

7. Savi P, Zachayus JL, Delesque-Touchard N, et al. The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci USA. 2006;103(29):11069-11074.

8. Nakagawa T, Takahashi C, Matsuzaki H, et al. N-glycan-dependent cell-surface expression of the P2Y2 receptor and N-glycan-independent distribution to lipid rafts. Biochem Biophys Res Commun. 2017;485(2):427-431.

9. Goto T, Kennel SJ, Abe M, et al. A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood. 1994;84(6):1922-1930.

10. Walter-Yohrling J, Cao X, Callahan M, et al. Identification of genes expressed in malignant cells that promote invasion. Cancer Res. 2003;63(24):8939-8947.

11. Erikson E, Adam T, Schmidt S, et al. In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317/BST-2/HM1.24/tetherin in humans. Proc Natl Acad Sci USA. 2011;108(33):13688-13693.

12. Rowley JW, Oler AJ, Tolley ND, et al. Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes. Proc Natl Acad Sci USA. 2014;111(26):E2579-E2588.

13. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. J Virol. 2005;79(9):5778-5786.

14. Billcliff PG, Rollason R, Prior I, Owen DM, Gaus K, Banting G. CD317/tetherin is an organiser of membrane microdomains. J Cell Sci. 2013;126(pt 7):1553-1564.

15. Kupzig S, Korolchuk V, Rollason R, Sugden A, Wilde A, Banting G. A CD317/tetherin-RICH2 complex plays a critical role in the organization of the subapical actin cytoskeleton in polarized epithelial cells. Cell Biol. 2009;184(5):721-736.

16. Perez-Caballero D, Zang T, Ebrahimi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110(4):1092-1097.

17. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110(4):1092-1097.

18. Shen B, Zhao X, O’Brien KA, et al. A directional switch of integrin signalling and a new anti-thrombotic strategy. Nature. 2013;503(7474):131-135.
22. Mundell SJ, Barton JF, Mayo-Martin MB, Hardy AR, Poole AW. Rapid resensitization of purinergic receptor function in human platelets. *J Thromb Haemost*. 2008;6(8):1393-1404.

23. Nisar SP, Cunningham M, Saxena K, Pope RJ, Kelly E, Mundell SJ. Arrestin scaffolds NHERF1 to the P2Y12 receptor to regulate receptor internalization. *J Biol Chem*. 2012;287(29):24505-24515.

24. Tsao PI, von Zastrow M. Type-specific sorting of G protein-coupled receptors after endocytosis. *J Biol Chem*. 2000;275(15):11130-11140.

25. Aungraheeta R, Conibear A, Butler M, et al. Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor. *Blood*. 2016;128(23):2717-2728.

26. Warren SC, Margineanu A, Alibhai D, et al. Rapid global fitting of large fluorescence lifetime imaging microscopy datasets. *PLoS One*. 2013;8(8):e70687.

27. Paulick MG, Bertozzi CR. The glycosylphosphatidylinositol anchor: a complex membrane-anchoring structure for proteins. *Biochemistry*. 2008;47(27):6991-7000.

28. Zhang K, Zhang J, Gao ZG, et al. Structure of the human P2Y12 receptor in complex with an antithrombotic drug. *Nature*. 2014;509(7498):115-118.

29. Zhang J, Zhang K, Gao ZG, et al. Agonist-bound structure of the human P2Y12 receptor. *Nature*. 2014;509(7498):119-122.

30. Namkung Y, Le Gouill C, Lukashova V, et al. Monitoring G protein-coupled receptor and β-arrestin trafficking in live cells using enhanced bystander BRET. *Nat Commun*. 2016;7(1):12178.

31. Cunningham MR, Nisar SP, Cooke AE, Emery ED, Mundell SJ. Differential endosomal sorting of a novel P2Y12 purinoreceptor mutant. *Traffic*. 2013;14(5):585-598.

32. Geyer HL, Mesa RA. Therapy for myeloproliferative neoplasms: when, which agent, and how? *Hematology Am Soc Hematol Educ Program*. 2014;2014:277-286.

33. Rumi E, Cazzola M. How I treat essential thrombocythemia. *Blood*. 2016;128(20):2403-2414.

34. Sauter D. Counteraction of the multifunctional restriction factor tetherin. *Front Microbiol*. 2014;5:163.

35. Galés C, Rebois RV, Hogue M, et al. Real-time monitoring of receptor and G-protein interactions in living cells. *Nat Methods*. 2005;2(3):177-184.

36. Baker A, Saulière A, Dumas F, et al. Functional membrane diffusion of G-protein coupled receptors. *Eur Biophys J*. 2007;36(8):849-860.

37. Gutman HH, Schachter J, Stopel E, Gutman R, Lahav J. Impaired platelet aggregation in melanoma patients treated with interferon-alpha-2b adjuvant therapy. *Cancer*. 2002;94(3):780-785.

38. Panasiuk A, Prokopowicz D, Zak J, Panasiuk B, Wysocka J. Inhibition of activated blood platelets by interferon alpha 2b in chronic hepatitis C. *Hepatogastroenterology*. 2004;51(59):1417-1421.